Table 2. Univariate and multivariate analysis of factors associated with progression-free and overall survival in all patients.
| Clinical Characteristics | Progression-Free Survival | Overall Survival | ||||
|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||
| P-value | RR (95% CI) | P-value | P-value | RR (95% CI) | P-value | |
| Age > 60 years | 0.111 | 0.207 | ||||
| Gender, male | 0.486 | 0.419 | ||||
| ECOG PS ≥ 2 | 0.042 | 0.044 | ||||
| B symptoms | 0.064 | 0.115 | ||||
| Elevated serum LDH | 0.001 | < 0.001 | ||||
| Stage II | < 0.001 | 2.761(1.188-6.416) | 0.018 | 0.003 | 4.110(1.233-13.695) | 0.021 |
| Pre-treatment EBV-DNA level (positive) | < 0.001 | 0.004 | ||||
| Post-treatment EBV-DNA level (positive) | < 0.001 | < 0.001 | ||||
| Pre-treatment sPD-L1 level>3.23 ng/mL | < 0.001 | < 0.001 | ||||
| Post-treatment sPD-L1 level>1.12 ng/mL | < 0.001 | 6.338(2.203-18.232) | 0.001 | < 0.001 | 6.515(1.912-22.203) | 0.003 |
| IPI score ≥ 2 | 0.009 | 0.013 | ||||
| KPI score ≥ 2 | 0.002 | 0.006 | ||||
| Treatment response (non-CR) | < 0.001 | 2.918(1.296-6.572) | 0.010 | < 0.001 | 7.041(1.540-32.203) | 0.012 |
Abbreviations: PFS, progression-free survival; OS, overall survival; RR, relative risk; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; IPI, International Prognostic Index; KPI, Korean Prognostic Index.